Cross-institution positioning
Oct 7, 2026Accumulation leaning. 2 accumulating across 2 comparable institutions.
Source: Schedule 13 researchABUS Institutional Ownership
Arbutus Biopharma Corp
Latest stored close $4.22 as of Oct 9, 2026 View live quote ↗
STOCKNODE Outlook
Neutral
Multi-institution accumulation
61/100
2 tracked · 2 comparable
Latest filing
Oct 7, 2026
Positive breadth
2 positive · 0 negative
Recent close
$4.22
Research confidence
Limited
Institutional Research 66/100 · 2 accumulating · 0 reducing / exited
Ownership history
Reported ownership % history
Latest filing Oct 7, 2026
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
Locked preview
Unlock the reported ownership timeline
Unlock full research
Accumulating2
Newly reported0
Reducing / exited
0
52-week position
—
Institutional Intelligence
Why STOCKNODE says Neutral
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
STOCKNODE Outlook
Neutral 61/100
Confidence:Limited
Why this signal
- 2 tracked institutions accumulating versus 0 reducing/exited.
- 1 tracked institution recently reversed from reducing to accumulating.
- Latest comparable Form 13F activity is net positive across tracked managers.
Institutional
70/100
Insiders
50/100
Fundamentals
43/100
Events
50/100
Quarterly 13F activity
Jun 30, 20262 increased/new, 0 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsInsider filing activity
Oct 1, 2026Recent Forms 3/4/5 activity is available, with no non-amendment non-derivative SEC-coded P/S transactions in the rolling 90-day window. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/5Material company events
Aug 21, 20263 non-amendment material events in the last 90 days; Latest classified evidence: Other event. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataSEC fundamentals
Aug 12, 2026Revenue -90.6% YoY; Net income -303.8% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsPrice context
Sep 15, 2026Recent close is 80% through its reported 52-week range; +11.7% over one year.
Source: Stored historical price series
Latest filing decision brief
Investor / Pro
Research the latest Schedule 13G amendment from Morgan Stanley.
Filed Oct 7, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
Supporting institutional evidence
Institutional Evidence
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
Latest filing
Oct 7, 2026
Latest reported position changes
Investor / Pro detailSee each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Morgan Stanley
Filed Oct 7, 2026
Direction locked
BlackRock
Filed Feb 12, 2024
Direction locked
Unlock the actual direction, share change, ownership change, and classification basis.
No premium position values are sent in this locked preview.
Unlock full research
Reported direction breadth by as-of date
Locked previewComparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Unlock actual accumulation vs. reduction breadth across reported position dates.
View plans
Institution comparison
Investor / Pro detailCompare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Morgan Stanley
Filed Oct 7, 2026
BlackRock
Filed Feb 12, 2024
Unlock the evidence behind the score
Know who changed position, by how much, and when the SEC learned about it.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
✓ Actual share and ownership changes
✓ Position as-of date vs. SEC filed date
✓ Deterministic direction basis
✓ Full evidence on every eligible stock
SEC Forms 3, 4 & 5
Insider activity
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
30-day purchases00 reporting owner(s)
30-day sales00 reporting owner(s)
90-day purchase breadth0
90-day sale breadth0
View recent insider filing evidence
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Oct 1, 2026 | Androski Lindsay | DDisposition to issuer | Common Shares | 24.7K | $5.00 | Direct | Oct 7, 2026 |
| Oct 1, 2026 | Sawhney Roger | DDisposition to issuer | Common Shares | 17.1K | $5.00 | Direct | Oct 7, 2026 |
| Oct 1, 2026 | Nguyen Tuan | DDisposition to issuer | Common Shares | 48.1K | $5.00 | Direct | Oct 7, 2026 |
| Oct 1, 2026 | Beardsley Robert A | DDisposition to issuer | Common Shares | 17.9K | $5.00 | Direct | Oct 7, 2026 |
| Oct 1, 2026 | Roivant Sciences Ltd. | DDisposition to issuer | Common Shares | 9.0M | $5.00 | Direct | Oct 5, 2026 |
| Sep 18, 2026 | Beardsley Robert A | MExercise or conversion of derivative · derivative | Stock Option (Right to Buy) | 78.8K | $0.00 | Direct | Sep 23, 2026 |
| Sep 18, 2026 | Beardsley Robert A | MExercise or conversion of derivative · derivative | Stock Option (Right to Buy) | 52.5K | $0.00 | Direct | Sep 23, 2026 |
| Sep 18, 2026 | Beardsley Robert A | FTax/price withholding or payment | Common Shares | 99.1K | $5.07 | Direct | Sep 23, 2026 |
| Sep 18, 2026 | Beardsley Robert A | MExercise or conversion of derivative | Common Shares | 78.8K | $4.24 | Direct | Sep 23, 2026 |
| Sep 18, 2026 | Beardsley Robert A | MExercise or conversion of derivative | Common Shares | 52.5K | $3.20 | Direct | Sep 23, 2026 |
| Sep 18, 2026 | Sawhney Roger | MExercise or conversion of derivative · derivative | Stock Option (Right to Buy) | 78.8K | $0.00 | Direct | Sep 23, 2026 |
| Sep 18, 2026 | Sawhney Roger | MExercise or conversion of derivative · derivative | Stock Option (Right to Buy) | 52.5K | $0.00 | Direct | Sep 23, 2026 |
| Sep 18, 2026 | Sawhney Roger | FTax/price withholding or payment | Common Shares | 100.5K | $5.07 | Direct | Sep 23, 2026 |
| Sep 18, 2026 | Sawhney Roger | MExercise or conversion of derivative | Common Shares | 78.8K | $4.24 | Direct | Sep 23, 2026 |
| Sep 18, 2026 | Sawhney Roger | MExercise or conversion of derivative | Common Shares | 52.5K | $3.34 | Direct | Sep 23, 2026 |
| Sep 18, 2026 | Nguyen Tuan | MExercise or conversion of derivative · derivative | Stock Option (Right to Buy) | 27.5K | $0.00 | Direct | Sep 23, 2026 |
| Sep 18, 2026 | Nguyen Tuan | MExercise or conversion of derivative · derivative | Stock Option (Right to Buy) | 265.6K | $0.00 | Direct | Sep 23, 2026 |
| Sep 18, 2026 | Nguyen Tuan | FTax/price withholding or payment | Common Shares | 206.6K | $5.07 | Direct | Sep 23, 2026 |
| Sep 18, 2026 | Nguyen Tuan | MExercise or conversion of derivative | Common Shares | 27.5K | $4.39 | Direct | Sep 23, 2026 |
| Sep 18, 2026 | Nguyen Tuan | MExercise or conversion of derivative | Common Shares | 265.6K | $3.49 | Direct | Sep 23, 2026 |
SEC company-event context
Material company events
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
30-day material events0
90-day capital-related0
90-day equity-related0
90-day debt-related0
View recent company-event filing evidence
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Aug 21, 2026 | 8-K | 8.01, 9.01 | Other event; Financial statements / exhibits | — | Filing |
| Aug 12, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Jul 16, 2026 | 8-K | 1.02, 5.02, 8.01, 9.01 | Termination of material agreement; Director or executive change; Other event; Financial statements / exhibits | — | Filing |
| Jun 5, 2026 | S-8 | — | Employee-plan securities registration | Equity | Filing |
| May 27, 2026 | 8-K | 5.02, 5.07, 9.01 | Director or executive change; Shareholder vote results; Financial statements / exhibits | — | Filing |
| May 13, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Apr 15, 2026 | 8-K | 8.01, 9.01 | Other event; Financial statements / exhibits | — | Filing |
| Mar 23, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Mar 3, 2026 | 8-K | 1.01, 8.01, 9.01 | Material definitive agreement; Other event; Financial statements / exhibits | — | Filing |
| Feb 20, 2026 | 8-K | 8.01, 9.01 | Other event; Financial statements / exhibits | — | Filing |
| Feb 6, 2026 | 8-K | 8.01, 9.01 | Other event; Financial statements / exhibits | — | Filing |
| Jan 16, 2026 | 8-K | 8.01, 9.01 | Other event; Financial statements / exhibits | — | Filing |
SEC-reported company fundamentals
Fundamentals
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
Revenue
$1.0M
Q2 2026
-90.6% YoY 10-Q filed Aug 12, 2026
Operating income
$-6.0M
Q2 2026
-500.8% YoY 10-Q filed Aug 12, 2026
Operating margin
-588.2%
Q2 2026
-602.0 pts YoY 10-Q filed Aug 12, 2026
Net income
$-5.1M
Q2 2026
-303.8% YoY 10-Q filed Aug 12, 2026
Diluted EPS
$-0.03
Q2 2026
-400.0% YoY 10-Q filed Aug 12, 2026
Operating cash flow
$-14.1M
YTD through Jun 30, 2026
+51.5% YoY 10-Q filed Aug 12, 2026
Free cash flow
$-39.6M
FY 2025
+39.1% YoY 10-K filed Mar 23, 2026
Cash & equivalents
$19.2M
As of Jun 30, 2026
-48.8% YoY 10-Q filed Aug 12, 2026
Assets
$274.0M
As of Jun 30, 2026
+165.4% YoY 10-Q filed Aug 12, 2026
Liabilities
$15.3M
As of Jun 30, 2026
-24.6% YoY 10-Q filed Aug 12, 2026
Stockholders’ equity
$258.7M
As of Jun 30, 2026
+211.8% YoY 10-Q filed Aug 12, 2026
Shares outstanding
197.8M
As of Aug 10, 2026
+3.2% YoY 10-Q filed Aug 12, 2026
View recent revenue trend
Quarterly
| Period | Revenue | YoY |
|---|---|---|
| Ended Jun 30, 2026 | $1.0M | -90.6% |
| Ended Mar 31, 2026 | $179.1M | +10,054.5% |
| Ended Sep 30, 2025 | $529.0K | -60.5% |
| Ended Jun 30, 2025 | $10.7M | +522.2% |
Annual
| Period | Revenue | YoY |
|---|---|---|
| Ended Dec 31, 2025 | $14.1M | +128.2% |
| Ended Dec 31, 2024 | $6.2M | -66.0% |
| Ended Dec 31, 2023 | $18.1M | -53.5% |
| Ended Dec 31, 2022 | $39.0M | +255.1% |
Current market context
Price performance
Dated price context from the historical market series already collected for this security.
Recent stored close
$5.06
View live quote ↗
52-week low
$3.50
Feb 2, 2026
52-week high
$5.45
Aug 21, 2026
Below 52-week high
7.2%
1W return
-2.3%
1M return
+8.4%
3M return
+17.1%
6M return
+18.8%
YTD return
+5.2%
1Y return
+11.7%
30-day volatility
36.4%
90-day volatility
39.1%
1Y max drawdown
-25.9%
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
How to read Schedule 13 ownership changes
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
Current ownership filings and reported ownership changes are available on free access. Investor and Pro add filing-specific significance scoring, disclosure-speed analysis, confirmation/divergence signals, and alerts. The overall institutional consensus preview remains public. Compare plans.
Beneficial ownership filing history
Showing 3 of 9 filing(s) · 6 older require more history accessView beneficial ownership filing evidence
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Morgan Stanley CIK0000895421 | Sep 30, 2026 observed Oct 7, 2026 filed · 7d Schedule 13G amendment | Reported accumulation | 18.7M +1.3M | 12.20% +3.40 pts | $4.78 | $4.29 | $4.22 |
| Morgan Stanley CIK0000895421 | Jun 30, 2026 observed Aug 12, 2026 filed · 43d Schedule 13G amendment | Reported reduction | 17.4M -8.5M | 8.80% -4.70 pts | $4.80 | $4.59 | $4.22 |
| Morgan Stanley CIK0000895421 | Dec 31, 2025 observed Feb 11, 2026 filed · 42d Schedule 13G amendment | Reported accumulation | 25.9M +4.4M | 13.50% +2.10 pts | $4.81 | $4.16 | $4.22 |
Explore more institutional activity
Related research
Compare ABUS with other securities showing similar institutional activity or recent accumulation across several tracked institutions.